Virax Biolabs Group Limited - Ordinary Shares (VRAX)
NASDAQ · Healthcare
$3.89+2.64%
As of Jul 20, 2026
Price history
Key statistics
- Market cap
- $1.19M
- P/E ratio
- —
- EPS
- —
- Volume
- 310,880
- 52-week high
- —
- 52-week low
- —
- Open
- $3.71
- Day high
- $4.11
- Day low
- $3.60
Financial highlights
Annual financials for Virax Biolabs Group Limited - Ordinary Shares are being compiled and will appear here soon.
About Virax Biolabs Group Limited - Ordinary Shares
Virax Biolabs Group Limited is a biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. The company is developing T cell-based test technologies intended to support an immunology profiling platform, with potential applications in post-acute infection syndromes, including Long COVID, and other chronic conditions linked to immune dysregulation.
- CEO
- James Foster
- Employees
- 19
- Country
- GB
- IPO date
- Jul 21, 2022
Similar stocks
Other Healthcare companies
Frequently asked questions
- What is Virax Biolabs Group Limited - Ordinary Shares's stock price today?
- VRAX is trading at $3.89 as of Jul 20, 2026.
- What is Virax Biolabs Group Limited - Ordinary Shares's market cap?
- Virax Biolabs Group Limited - Ordinary Shares (VRAX) has a market capitalization of $1.19M.
- What sector is Virax Biolabs Group Limited - Ordinary Shares in?
- Virax Biolabs Group Limited - Ordinary Shares operates in the Healthcare sector.